Minimal residual disease (MRD) in CLL is defined as the number of leukemic cells that can be detected in peripheral blood (PB) or bone marrow (BM) following treatment. Undetectable MRD (uMRD) is currently defined as the presence of less than 1 CLL cell in 10,000 leukocytes (<10 −4). 2

Dec 30, 2021 · Routine clinical, laboratory, and imaging methods do not currently detect occult residual tumor, which is referred as minimal (or, more precisely, measurable or detectable) residual disease (MRD).

Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected. This test can detect an extremely small number of cancer cells that cannot be found through traditional laboratory testing methods.

Jun 24, 2021 · We recommend “MRD4” to identify cases with <10 −4 MRD (<1 CLL cell per 10 000 leukocytes, or <0.01%), “MRD5” to identify cases with <10 −5 MRD (<1 CLL cell per 100,000 leukocytes, or ...

Mar 20, 2024 · One of the newest tools is testing for MRD, or measurable (AKA minimal) residual disease, which can detect very low levels of CLL in the blood or in the bone marrow, as explained in this basic article by Dr. Brian Koffman. This can help inform optimal management.

• MRD can help identify which patients are at higher risk for relapse, allowing for earlier or additional treatments. MRD may also determine which patients may benefit from a bone marrow transplantation. Chronic Lymphocytic Leukemia (CLL) • MRD is detected by flow cytometry and PCR. • Patients who remain MRD negative after the end of

Dec 8, 2023 · Detection of measurable residual disease (MRD) is a sensitive tool to identify disease burden following treatment with several therapeutic regimens in CLL (including CIT, venetoclax-based regimens, and cellular therapies), and it has demonstrated prognostic value.

Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia.

Feb 20, 2025 · Preliminary data from this study suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable measurable residual disease (uMRD) may be able to discontinue therapy early. MRD testing appears helpful in guiding decisions about treatment duration in patients with CLL.

Nov 5, 2020 · In CLL, undetectable MRD at the end of treatment in peripheral blood or bone marrow is associated with long-term survival (Thompson et al, Leukemia 2018). The international workshop on CLL (iwCLL) guidelines for response assessment in CLL now incorporate MRD assessment (Hallek, et al, Blood 2018).